Abecma

Abu Dhabi · access guide

How to access Abecma for relapsed or refractory multiple myeloma from Abu Dhabi: 2026 in-emirate pathway via CCAD, SSMC, and ADSCC

By Reserve Meds clinical & regulatory team. Last reviewed 2026-05-20.

Abu Dhabi is the UAE's documented advanced-cell-therapy hub. Cleveland Clinic Abu Dhabi, Sheikh Shakhbout Medical City, the Abu Dhabi Stem Cells Center, and Burjeel Medical City run adult haematology and bone marrow transplant programmes with active cell therapy alignment, and the Department of Health Abu Dhabi was the regulator that coordinated the UAE's first commercial Casgevy administration at Yas Clinic Hospital in April 2026. Abecma is registered with the Emirates Drug Establishment, and for an Abu Dhabi resident with triple-class-exposed relapsed or refractory multiple myeloma the operational question is which in-emirate certified centre fits the case, how the Thiqa or commercial-insurance pre-authorisation conversation runs alongside the clinical referral, and what the four-week REMS-restricted post-infusion period reshapes in family logistics. This page describes the 2026 pathway: who qualifies, where the workup happens, where apheresis and infusion sit, what the timeline looks like, what the realistic cost band is, and when a cross-border or commercial-bispecific alternative is the right call instead.

Why Abu Dhabi is the operational centre of gravity

The Department of Health Abu Dhabi positioned the emirate as the UAE's national reference for advanced cellular and gene therapies through deliberate regulatory and infrastructure investment. Sheikh Khalifa Medical City performed the UAE's first paediatric Duchenne muscular dystrophy gene transfer therapy with Elevidys on 19 March 2024 under DoH coordination. Yas Clinic Hospital, with the Abu Dhabi Stem Cells Center as regulatory and clinical co-ordinator, administered the UAE's first commercial Casgevy CRISPR cell therapy for sickle cell disease in April 2026. The same infrastructure depth applies to adult cell therapy programmes building toward commercial BCMA CAR-T capability.

Cleveland Clinic Abu Dhabi runs the most established adult haematology and BMT programme in the emirate. Sheikh Shakhbout Medical City, with its MD Anderson Cancer Center affiliation, has built a deep oncology bench and accepts adult cell therapy referrals. The Abu Dhabi Stem Cells Center has expanded from its bone marrow transplant origins into ATMP coordination across the emirate. Burjeel Medical City's oncology and BMT programme integrates into the broader Burjeel and ADHC networks. For an Abu Dhabi-resident adult, this concentration of cell therapy capability is unusual in regional terms and means the cross-border step that Bahrain, Kuwait, and Oman patients confront is not the default operational reality.

What Abecma is, in plain language

Abecma is idecabtagene vicleucel, an autologous BCMA-directed CAR T-cell therapy developed by Bristol Myers Squibb in partnership with 2seventy bio. It was the first cell therapy approved anywhere for multiple myeloma, reaching the US market in March 2021. The 2024 label expansion brought eligibility forward to adults with two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. That expansion was based on the KarMMa-3 randomised Phase 3 trial, which compared a single Abecma infusion against investigator's choice of five standard regimens in 386 triple-class-exposed patients. Median progression-free survival on Abecma was 13.3 months versus 4.4 months for standard of care, with overall response rate 71 percent versus 42 percent.

A small volume of the patient's own blood is collected by apheresis. The T cells are sent to BMS's manufacturing facility, where they are transduced with a lentiviral vector that teaches them to recognise BCMA, a protein expressed almost exclusively on plasma cells and myeloma cells. The engineered T cells expand to therapeutic dose over four to five weeks. While manufacturing happens, the patient continues bridging therapy to control disease burden. When the product is ready, three days of fludarabine plus cyclophosphamide lymphodepletion make room for the CAR-T cells to expand in vivo, then a single intravenous infusion of the manufactured Abecma. Inpatient monitoring for cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome typically runs seven to fourteen days. The patient and a caregiver then stay within two hours of the treating centre for four weeks for REMS-mandated monitoring.

This is a one-time cell therapy, not a chronic medication. The operational complexity sits in the apheresis, the manufacturing wait, the lymphodepletion, the inpatient infusion stay, and the post-infusion month.

Eligibility at an Abu Dhabi haematologist's clinic

For Abu Dhabi resident adults, the FDA and EMA criteria apply with local adaptation by the certified centre's cell therapy committee:

1. Confirmed relapsed or refractory multiple myeloma after two or more prior lines including an IMiD, a PI, and an anti-CD38 monoclonal antibody. 2. ECOG performance status 0 to 1; ECOG 2 reviewed case by case. 3. Adequate left ventricular ejection fraction, typically 45 percent or greater. 4. Adequate pulmonary, hepatic, renal, and bone-marrow reserve. 5. No active CNS involvement of myeloma. 6. No active infection requiring systemic therapy. 7. A bridging therapy plan agreed with the treating haematologist for the four to five week manufacturing window. 8. A caregiver commitment for the four-week REMS-restricted period after infusion.

An Abu Dhabi patient should arrive at the cell therapy referral conversation with the most recent diagnostic workup in hand: serum and urine protein electrophoresis with immunofixation, serum free light chain assay, bone marrow biopsy and aspirate with cytogenetics including FISH for high-risk markers (del17p, t(4;14), t(14;16), gain 1q), skeletal survey or whole-body MRI, PET-CT, beta-2-microglobulin, albumin, and a current treatment history with response durations. Reserve Meds organises this documentation pack so the certified centre can give a yes or no eligibility opinion on the first review, not the fifth.

The certified-centre picture in Abu Dhabi

In 2026 the Abu Dhabi adult haematology and cell therapy bench relevant to a commercial Abecma case includes:

- Cleveland Clinic Abu Dhabi (CCAD), with the deepest in-emirate adult haematology and BMT programme. Active interest in expanding adult cell therapy services. CAR-T programme alignment for commercial BCMA products is evolving; confirm current authorisation status at intake. - Sheikh Shakhbout Medical City (SSMC), with an MD Anderson Cancer Center affiliation and an adult haematology service that takes cell therapy referrals. - Abu Dhabi Stem Cells Center (ADSCC), which coordinated the regulatory and clinical pathway for the UAE's first Casgevy gene therapy in April 2026 alongside Yas Clinic. ATMP coordination and cell therapy registry capability extends to adult haematology cases. - Burjeel Medical City, with an oncology and BMT programme integrated into the broader Burjeel and ADHC network footprint. - Yas Clinic Hospital, the UAE's first Casgevy administration site (April 2026), with cell therapy administration infrastructure that may extend to BCMA CAR-T as commercial authorisation progresses.

For Abu Dhabi-resident adults where the in-emirate certified centre's authorisation timing is incompatible with the disease tempo, the cross-border alternatives include King Faisal Specialist Hospital and Research Centre Riyadh (long-established BMT and cellular therapy programme with deep CAR-T experience), King Hussein Cancer Center Amman (the largest dedicated cancer centre in MENA with adult cell therapy accreditation), and select European or US centres for patients with international medical coverage.

The 2026 pathway, step by step

Week 0 to 2: Reserve Meds builds the document pack with the treating haematologist's office. We collect imaging, marrow biopsy, cytogenetics, treatment history, and laboratory panels. We submit a first-review request to one or two Abu Dhabi certified cell therapy programmes in parallel so a single slow response does not stall the process.

Week 2 to 4: The Abu Dhabi certified centre's cell therapy committee reviews the case. If accepted, the centre opens a BMS manufacturing slot and schedules apheresis. The financial pre-authorisation conversation starts in parallel; Thiqa coverage for Emirati nationals is the dominant cover and the pre-authorisation conversation needs to start before apheresis, not after infusion. Daman, AXA Gulf, and other commercial covers vary in cell therapy coverage; out-of-pocket exposure ranges are clarified before commitment.

Week 4 to 5: Apheresis at the certified Abu Dhabi centre. One to two sessions, outpatient, typically a single half-day. The collected T cells are shipped to BMS for ex-vivo manufacturing.

Week 5 to 9: Manufacturing wait. The patient continues bridging therapy under the treating haematologist's direction. Bridging regimens are physician-choice and depend on prior exposures and refractoriness profile.

Week 9: Three days of fludarabine plus cyclophosphamide lymphodepletion as outpatient or short-stay inpatient.

Week 9 to 10: Single inpatient Abecma infusion at the certified Abu Dhabi centre. Day 0 of the cell therapy clock.

Week 10 to 11: Inpatient monitoring for CRS and ICANS, typically seven to fourteen days. Tocilizumab and corticosteroids per protocol.

Week 11 to 14: REMS-restricted four-week post-infusion period. Patient and caregiver stay within two hours of the treating centre. For an Abu Dhabi resident this means staying at home or in nearby family accommodation, a meaningful operational advantage over cross-border or cross-emirate pathways. No driving. Twice-weekly clinic visits. Infection precautions.

Month 4 onwards: Outpatient follow-up. Monthly disease assessment for the first year; then quarterly. Long-term haematology surveillance for cytopenias, infections, hypogammaglobulinaemia, and second-primary malignancies.

Cost expectation in AED

US list price for the Abecma product itself is USD 419,500 (some 2024 wholesale acquisition cost references quote USD 498,410; confirm at intake for any commercial contract). Real-world total cost of care including apheresis, bridging therapy, lymphodepletion, inpatient infusion and monitoring, CRS or ICANS management, and one-year follow-up commonly runs USD 700,000 to USD 1.0 million in US data. At 2026 indicative cross rates the AED-equivalent product price is approximately AED 1.54 million and the total cost of care band is approximately AED 2.6 to 3.7 million. An Abu Dhabi-resident pathway avoids the cross-border accommodation overhead that other GCC pathways carry, which can sit toward the lower end of the band on the right case.

Thiqa coverage for Emirati nationals has historically extended to authorised advanced therapies on a case-by-case basis. The Thiqa pre-authorisation conversation runs in parallel with the clinical pre-authorisation conversation at the certified centre and is the gating step for an Emirati national case. For non-national residents on Daman, AXA Gulf, or other commercial covers, the cell therapy coverage varies and the financial review is the gating step before apheresis scheduling.

Religious, ethical, and family-logistics framing

Cell-based therapy sits within the Islamic jurisprudential framework that already permits blood transfusion, organ transplantation, and assisted reproduction with appropriate safeguards. Abecma is the patient's own T cells engineered ex vivo and re-infused; there is no donor element, the lentiviral vector is a research tool used during manufacturing rather than a permanent transgenic modification of germline tissue, and the cells return to a patient whose marrow and immune system remain their own. The dominant ethical frame in MENA Islamic medical ethics for this kind of therapy has been permissive, with the standard expectation that the family makes the treatment decision in consultation with the treating physician and according to the patient's own informed wish.

The family-logistics burden of the four-week REMS-restricted post-infusion period is the practical pressure point even when the pathway runs entirely in-emirate. A caregiver must be present continuously; Abu Dhabi families typically build a rotating caregiver schedule across two or three relatives. The patient cannot drive; transport to twice-weekly clinic visits needs to be arranged. Friday prayer attendance at the patient's usual mosque may need to be adapted to the immunocompromised period; the treating team's infection-precaution guidance shapes which gatherings remain feasible. Reserve Meds documents the transport, pharmacy delivery, infection-precaution, and family-rotation logistics in advance so the family arrives prepared rather than improvising on day 14 of an inpatient stay.

When the Abu Dhabi pathway is not the right call

For an Abu Dhabi-resident patient where the in-emirate certified centre's authorisation timing for commercial Abecma is incompatible with the disease tempo, the operational alternatives include:

- King Faisal Specialist Hospital and Research Centre (KFSHRC) Riyadh, which runs the deepest regional CAR-T programme with more than two hundred CAR-T patients treated since 2020 and opened the kingdom's first in-house point-of-care CAR-T manufacturing facility in late 2025. A 90-minute direct flight from Abu Dhabi. - King Hussein Cancer Center (KHCC) Amman, the largest dedicated cancer centre in MENA, accredited for adult cell therapy. - Select European or US certified cell therapy centres for patients with international medical coverage.

A separate operational alternative is a BCMA-directed bispecific T-cell engager such as Tecvayli (teclistamab) or Elrexfio (elranatamab), which are off-the-shelf, require step-up admission rather than apheresis, and have no manufacturing wait. Talvey (talquetamab) targets GPRC5D rather than BCMA and is the alternative bispecific when BCMA exposure has already happened. The other commercial BCMA CAR-T product, Carvykti (ciltacabtagene autoleucel), is accessible in select certified centres internationally; comparative eligibility is a clinical conversation rather than a one-size-fits-all default.

Reserve Meds does not push a default. The page above describes the Abecma pathway because Abecma is the BCMA CAR-T the patient has asked about. If the conversation with the treating haematologist points toward a bispecific or a different cell therapy, the operational pathway shifts accordingly and we coordinate that pathway instead.

What Reserve Meds does on this case

We are a US-based concierge coordinator. We are not the prescriber and not the dispensing pharmacy. On an Abu Dhabi Abecma case we build the document pack, submit first-review requests to one or two Abu Dhabi certified centres in parallel, run the financial pre-authorisation conversation alongside the clinical pre-authorisation conversation (Thiqa for Emirati nationals, Daman or other commercial covers for residents), coordinate the bridging-therapy logistics during the manufacturing window, organise the proximity logistics and caregiver schedule for the four-week REMS-restricted period, and stay with the case through one-year follow-up. Clinical decisions remain with your treating haematologist and the certified cell therapy programme.

Reserve Meds's role

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

reservemeds.com · hello@reservemeds.com